-
AZD6482: A Context-Aware PI3Kβ Research Guide
2026-09-12
Explore AZD6482 as a selective PI3Kβ inhibitor through a context-aware framework linking target engagement, platelet biology, metabolic assays, and RNA-foci study design. Learn how to interpret its selectivity without conflating PI3Kβ signaling with HSP90-dependent regulation in DM1.
-
Ibotenic Acid: Workflows for NMDA Research
2026-09-12
Build more informative glutamatergic assays with Ibotenic acid, combining receptor-driven activity changes with behavioral, biochemical, c-fos, and Nissl readouts. This practical guide distinguishes formulation controls from literature-based toxicity observations so the compound can be deployed as a neuroscience research tool with clearer interpretation and better reproducibility.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-09-11
A 2022 Journal of Molecular Medicine study identified ziprasidone as a noncompetitive inhibitor of GOT1, linking a known antipsychotic scaffold to glutamine-metabolism disruption in pancreatic ductal adenocarcinoma. Its combination of biochemical, metabolomic, cellular, genetic, and xenograft evidence supports GOT1 as a mechanistically relevant vulnerability, while also highlighting the substantial work needed before clinical translation.
-
Triiodothyronine and Adipose Thermogenesis
2026-09-11
Triiodothyronine (T3) provides a receptor-level way to interrogate adipose thermogenesis. This article connects T3 assay design with SETD7-dependent white adipose browning while separating established evidence from testable metabolic hypotheses.
-
Phytol Workflows for RXR Assays and Nanomaterials
2026-09-10
Phytol is a practical probe for retinoid X receptor signaling, but its insolubility, isomeric composition, and GABAergic activity demand disciplined assay design. This guide combines concentration-control workflows with lessons from shaped coil-bottlebrush self-assembly research to improve reproducibility in receptor, cell, and exploratory materials studies.
-
Gepotidacin for Uncomplicated Urogenital Gonorrhea
2026-09-10
This phase 2 randomized study evaluated whether a single oral dose of gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infection. Both 1500-mg and 3000-mg doses produced high microbiological cure rates, while treatment failures were associated with a shared bacterial mutation and the highest observed gepotidacin MIC.
-
L-Glutathione Reduced in Redox and GOT1 Workflows
2026-09-09
L-Glutathione Reduced provides a water-compatible way to probe thiol redox chemistry, GST purification, and metabolic stress in pancreatic cancer models. This guide connects practical reagent handling with the GOT1-focused findings of a 2022 PDAC study while separating validated evidence from assay-development recommendations.
-
Z-VDVAD-FMK Workflow for Caspase-2 Studies
2026-09-09
Z-VDVAD-FMK provides a cell-permeable, irreversible perturbation strategy for separating caspase-2-associated apoptosis from downstream caspase activity. This workflow connects mitochondrial, protein-level, and host-virus readouts while highlighting controls needed to avoid overinterpreting inhibitor data.
-
Ziprasidone Augmentation in Anxious Depression
2026-09-08
This post-hoc analysis examined whether baseline anxious depression modified the antidepressant and anxiolytic effects of ziprasidone added to escitalopram. The findings support comparable depressive symptom improvement across anxiety subgroups, but they do not establish a clinically meaningful anxiolytic benefit in patients with greater anxiety.
-
SU 5402 Workflows for Kinase Signaling Research
2026-09-08
SU 5402 enables practical dissection of VEGFR2, FGFR1, and PDGFRβ signaling in cancer biology, while its pathway-level effects can be adapted cautiously to human sensory neuron assays. This guide connects dose design, phospho-readouts, apoptosis assay planning, and the emerging hiPSC-derived HSV-1 latency model.
-
Anti-ROR1 Antibody: Applied Workflows
2026-09-07
Build reproducible ROR1 binding, surface-phenotyping, and pathway-blocking assays with Zilovertamab. The workflow also shows how to use the reagent cautiously as an exploratory perturbation in deoxynivalenol liver-injury studies without confusing cross-domain hypotheses with validated findings.
-
GLP-1 (9-36) amide: Assay Workflow Guide
2026-09-05
Build cleaner GLP-1 receptor experiments with a practical workflow for antagonist handling, cAMP assay controls, and receptor-crosstalk analysis. The guide distinguishes product-specific handling requirements from findings obtained with related antagonists in high-throughput FRET studies.
-
SU6656 Src Tyrosine Kinases Inhibitor Workflows
2026-09-05
SU6656 provides a practical way to probe Src-family signaling in megakaryocyte maturation, PDGF-driven proliferation, and endothelial responses to irradiation. This guide translates the 2026 hiPSC platelet study into assay-ready workflows while separating validated findings from pilot recommendations for cancer research.
-
GW 4869 in Exosome–Endothelial Assays
2026-09-04
GW 4869 enables researchers to test whether neutral sphingomyelinase activity and extracellular vesicle release causally connect podocyte stress with glomerular endothelial injury. This workflow combines pharmacologic inhibition with vesicle depletion, cargo analysis, and recipient-cell controls for more defensible lupus nephritis experiments.
-
BOP Reagent for Prodrug-Ready Peptide Chemistry
2026-09-04
BOP reagent enables controlled carboxyl group activation, amide bond formation, and phenyl ester preparation. This guide connects its reaction logic to assay decisions inspired by a carrier-free, ROS-responsive triterpene prodrug study.